WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 8 fonti

Lilly shares safety, tolerability data on its next-gen obesity drug

Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.

Raccontata da

morningstar.com

economictimes.indiatimes.com

newsbytesapp.com

markets.businessinsider.com

biopharmadive.com

fiercepharma.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 mesi fa

Lilly shares safety, tolerability data on its next-gen obesity drug

Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.

Timeline cronologica

sabato 6 giugno 2026·healio.com
Retatrutide benefits in obesity, type 2 diabetes ‘quite staggering’
NEW ORLEANS —A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an extent not seen with previous pharmacotherapy options,…
sabato 6 giugno 2026·morningstar.com
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea,…
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential…

economictimes.indiatimes.com

1 mesi fa

US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market

Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients ‌with obesity, ⁠at the ⁠American Diabetes Association meeting in New Orleans.

Leggi questa versione → originale

biopharmadive.com1 mesi fa

ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

Leggi questa versione → originale

markets.businessinsider.com1 mesi fa

Eli Lilly’s (LLY) New Drug Gives Investors a Wake-Up Call as Data Bolsters the Stock’s Growth Story

Eli Lilly and Company (LLY) gave investors another reason to watch its obesity pipeline after new late-stage data showed that its experimental d...

Leggi questa versione → originale

newsbytesapp.com1 mesi fa

Eli Lilly's obesity drug shows promise in treating sleep apnea

Eli Lilly's retatrutide significantly reduces sleep apnea severity, knee osteoarthritis pain, and promotes substantial weight loss in adults with obesity, trial results reveal.

Leggi questa versione → originale

fiercepharma.com1 mesi fa

With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race

It’s a sign of the times that this year’s American Diabetes Association (ADA) Scientific Sessions meeting in New Orleans featured more chatter on obesity drugs and pipeline programs than those spec | Eli Lilly emerged…

Leggi questa versione → originale

sabato 6 giugno 2026·

statnews.com

Lilly shares safety, tolerability data on its next-gen obesity drug

Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.

domenica 7 giugno 2026·

economictimes.indiatimes.com

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoarthritis pain in adults with obesity.…

domenica 7 giugno 2026·

newsbytesapp.com

Eli Lilly's obesity drug shows promise in treating sleep apnea

Eli Lilly's retatrutide significantly reduces sleep apnea severity, knee osteoarthritis pain, and promotes substantial weight loss in adults with obesity, trial results reveal.

domenica 7 giugno 2026·

markets.businessinsider.com

Eli Lilly’s (LLY) New Drug Gives Investors a Wake-Up Call as Data Bolsters the Stock’s Growth Story

Eli Lilly and Company (LLY) gave investors another reason to watch its obesity pipeline after new late-stage data showed that its experimental d...

domenica 7 giugno 2026·

statnews.com

New data may cast doubt on competitiveness of Boehringer’s obesity drug

Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.

domenica 7 giugno 2026·

statnews.com

Competition for obesity drugs, clinical blind spots, and more news from ADA

You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.

lunedì 8 giugno 2026·

biopharmadive.com

ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

lunedì 8 giugno 2026·

statnews.com

Pharmalittle: We're reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more

Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide

lunedì 8 giugno 2026·

economictimes.indiatimes.com

US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market

Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients ‌with obesity, ⁠at the ⁠American Diabetes…

lunedì 8 giugno 2026·

fiercepharma.com

With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race

It’s a sign of the times that this year’s American Diabetes Association (ADA) Scientific Sessions meeting in New Orleans featured more chatter on obesity drugs and pipeline…

lunedì 8 giugno 2026·

fiercepharma.com

ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes

With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break into Type 2 diabetes, in turn rounding out its oral…